Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

Merz Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Botulinum neurotoxin type A, free of complexing proteins

Study type

Interventional

Funder types

Industry

Identifiers

NCT00515944

MRZ 60201-0709/1

Details and patient eligibility

About

Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Full description

Conducted in Europe

Enrollment

30 estimated patients

Sex

Female

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: